- Diphtheria-tetanus-acellular pertussis (DTaP) vaccine confers imperfect but long-term immunologic protection.
- Modeling demonstrates that temporal trends do not adequately capture pertussis acquisition odds; measures of vaccine effectiveness are incomplete.
Why this matters
- DTaP vaccination is encouraged in all children per CDC guidance.
- Despite occasional periodic pertussis outbreaks, DTaP confers indirect, herd immunity.
- DTaP effectiveness in children ages 5-9 years exceeds 75%.
- Immunity appears to persist ≥5 years after last vaccine dose in ~65% (empirical OR, 1.33; 95% CI, 1.23-1.43).
- OR typically exceeds degree of waning effectiveness and correlates to ORs reported in literature (1.23-1.43).
- Age-structured, population-based modeling study quantifying duration of DTaP immunity in 5 pediatric cohorts tracked from age 5 to 9 years across 8 years.
- Funding: NIH.
- Limited sample.